TVGN — Tevogen Bio Holdings Income Statement
0.000.00%
Last trade - 00:00- $138.01m
- $152.17m
Annual income statement for Tevogen Bio Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 4.62 | 13.7 | 8.84 | 61.1 |
| Operating Profit | -4.62 | -13.7 | -8.84 | -61.1 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -15.6 | -22 | -60.5 | -13.7 |
| Net Income After Taxes | -15.6 | -22 | -60.5 | -13.7 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -15.6 | -22 | -60.5 | -13.7 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -15.6 | -22 | -60.5 | -10.3 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.101 | -0.142 | -0.391 | -0.019 |
| Dividends per Share |